Revenues grew 9% YoY to | 4082 crore, (I-direct estimate: | 4072 crore) mainly due to 12% growth in domestic formulations (GST adjusted growth was 19%) to | 1646 crore. US sales declined 6.5% YoY at | 617 crore (I-direct estimate: | 646 crore) EBITDA margins improved 156 bps YoY to 19.7%, and came above Idirect estimate of 19% mainly due to lower other expenditure. EBITDA grew 18% YoY to | 804 crore (I-direct estimate: | 774 crore) PAT grew 19% to | 423 crore (I-direct estimate: | 437 crore) mainly on better operational performance and higher other income....